Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

5531 - Health-related quality Of Life In patients with advanced Soft TIssue sarcomas treated with Chemotherapy: The HOLISTIC study

Date

28 Sep 2019

Session

Poster Display session 1

Presenters

Eugenie Younger

Citation

Annals of Oncology (2019) 30 (suppl_5): v683-v709. 10.1093/annonc/mdz283

Authors

E. Younger1, O. Husson2, I.M.E. Desar3, R. Young4, M.G. Leahy5, A. Oosten6, H. Gelderblom7, J. de Haan8, N. Steeghs9, R.L. Jones10, W.T. van der Graaf1

Author affiliations

  • 1 Sarcoma Unit, Royal Marsden Hospital NHS Foundation Trust, SW3 6JJ - London/GB
  • 2 Psychosocial Research And Epidemiology, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), 1066 CX - Amsterdam/NL
  • 3 Medical Oncology, Radboud University Medical Center, 6525 GA - Nijmegen/NL
  • 4 Medical Oncolog, Weston Park Hospital, Sheffield/GB
  • 5 Medical Oncology, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
  • 6 Medical Oncology Dept, Erasmus MC Daniel den Hoed Cancer Center, 3075EA - Rotterdam/NL
  • 7 Medical Oncology Dept, Leids Universitair Medisch Centrum (LUMC), 2333 ZA - Leiden/NL
  • 8 Medical Oncology, University Medical Center, Groningen/NL
  • 9 Medical Oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), 1066 CX - Amsterdam/NL
  • 10 Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, SW3 6JJ - London/GB
More

Resources

Abstract 5531

Background

Around half of patients with intermediate or high-grade soft tissue sarcomas (STS) will develop advanced disease. The mainstay of treatment for advanced STS is chemotherapy. Although treatment intent is usually palliative, the degree to which chemotherapy affects symptoms of disease, patient functioning and health-related quality of life (HRQoL) is rarely measured nor incorporated into clinical trials. Radiological response rates, time to progression and survival are traditionally used to measure treatment benefit. Therapeutic decisions are often challenging due to modest response rates and treatment-related adverse events. HRQoL is perceived by some patients as of equal- or greater importance than survival. Clinicians should be able to provide HRQoL data to patients to enhance the shared decision-making process and encourage a holistic approach to care. The aim of this study is to assess HRQoL in patients with advanced STS treated with 1st line chemotherapy, explore the decision-making process and evaluate patient post-treatment reflection.

Trial design

This is a longitudinal cohort study for patients aged ≥18 years with advanced STS (n = 132) who are treated with 1st line chemotherapy. Patients from 8 centres (United Kingdom 3, The Netherlands 5) are invited to complete questionnaires at baseline, each cycle of chemotherapy and three-monthly during follow-up. Data collection will be done within PROFILES, an established international registry for cancer patient reported outcomes. Questionnaires include patient demographics, decisional conflict scale, control preferences scale, quality-quantity questionnaire, treatment expectations, EORTC-QLQ-C30, FACT-G (2 items), work-ability index, financial toxicity and decisional regret scale. Clinical details, such as STS histology, will be collected from patient records and linked to questionnaire data. The primary endpoint is change in global HRQoL from baseline to Cycle 4 of chemotherapy. Exploratory endpoints include HRQoL functioning scales and symptoms. Recruitment started February 2018; 57 patients have completed (at least) the baseline questionnaire. (May 2019).

Clinical trial identification

NCT03621332.

Editorial acknowledgement

Legal entity responsible for the study

Institute of Cancer Research, London, United Kingdom and Radboud UMC, Nijmegen, Netherlands.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings